Borderline Ovarian Tumor Treatment Options and What to Expect

Borderline ovarian tumor treatment requires a specialized approach that balances oncological safety with quality of life considerations. These tumors, also known as low malignant potential tumors, present unique challenges that differ significantly from invasive ovarian cancer management.

Understanding your treatment options becomes crucial when facing this diagnosis. While borderline ovarian tumors have an excellent prognosis — with survival rates at approximately 90% at 10 years for early-stage disease — the path forward depends on multiple factors including your age, stage, and fertility goals.

What Makes Borderline Ovarian Tumor Treatment Different?

Unlike invasive ovarian cancer, borderline ovarian tumors account for 15% of all epithelial ovarian cancers and behave much less aggressively. These tumors are characterized by cellular abnormalities without the destructive invasion typical of cancer.

The treatment landscape has evolved significantly over recent decades. Where once radical surgery was standard, today’s approach emphasizes fertility preservation when appropriate. This shift reflects our growing understanding that nearly 75% of borderline tumors are stage I at diagnosis, offering more conservative treatment options.

Surgery: The Foundation of BOT Treatment

Surgery remains the cornerstone of borderline ovarian tumors treatment. The extent of surgery depends primarily on the stage of disease and your reproductive goals.

Early-Stage Treatment Options

For stage I and II borderline tumors, several surgical approaches exist:

Fertility-preserving options:

• Unilateral salpingo-oophorectomy (removing one ovary and fallopian tube)
• Ovarian cystectomy (removing only the tumor while preserving ovarian tissue)
• Bilateral cystectomy for bilateral disease

Standard surgical approach:

• Total hysterectomy with bilateral salpingo-oophorectomy
• Complete surgical staging including peritoneal washings, omentectomy, and peritoneal biopsies

The choice between these approaches involves careful consideration of recurrence risks. Conservative management has a significant impact on recurrence rates, with 5% to 34% recurrence after fertility-sparing surgery versus 3.2% to 7% after radical surgery.

Understanding Surgical Staging

Complete staging provides critical information for prognosis and follow-up planning, and is recommended. This includes:

• Peritoneal cytology
• Multiple peritoneal biopsies
• Omentectomy
• Careful inspection of all abdominal surfaces
• Appendectomy for mucinous borderline tumors

This means the surgeon carefully examines the entire abdomen, takes fluid samples to check for cancer cells, removes small tissue samples from various areas, removes part of the fatty tissue that covers the intestines (omentum), and removes any visible tumor deposits to determine how far the cancer has spread.

Advanced-Stage Borderline Ovarian Tumor Treatment

For stages III and IV disease, treatment becomes more complex. The presence and type of peritoneal implants significantly influence both treatment decisions and prognosis.

Surgical Debulking

Complete surgical removal (debulking surgery) of all visible disease remains the primary goal. Patients with stage III or IV disease with no gross residual tumor had a survival rate of 100% in some series, while those with residual disease had significantly worse outcomes.

The surgical approach for advanced disease typically includes:

• Total hysterectomy and bilateral salpingo-oophorectomy
• Aggressive cytoreductive surgery
• Complete removal of all visible implants
• Lymph node sampling when indicated

The Role of Implant Type

Understanding implant classification proves crucial for prognosis. When borderline ovarian tumors spread beyond the ovaries, they can form deposits called implants on the lining of the abdomen. These implants are classified as either invasive (growing into surrounding tissue) or noninvasive (sitting on the surface without penetrating deeper). Additionally, some serous borderline tumors may have micropapillary features, which represent a more aggressive variant that can behave similarly to invasive implants and may require closer monitoring and follow-up.

Among patients with peritoneal spread, invasive implants are found in one-fourth of patients and noninvasive implants in three-fourths of patients. Patients with noninvasive implants have much better outcomes than those with invasive implants, with the latter group requiring more aggressive treatment and closer follow-up.

Fertility-Sparing Treatment: Balancing Hope and Safety

For some patients, fertility preservation often becomes a primary concern. The treatment of borderline ovarian tumors in reproductive-age women requires careful counseling about risks and benefits.

Cystectomy vs. Oophorectomy

The debate between ovarian cystectomy and unilateral salpingo-oophorectomy continues in fertility-sparing treatment. In one study, the recurrence rates after cystectomy, unilateral salpingo-oophorectomy or bilateral salpingo-oophorectomy have been found as 30.3%, 11% and 1.7%, respectively.

Despite higher recurrence rates, cystectomy remains an option for:

• Unilateral disease
• Patients with only one ovary
• Young patients accepting higher recurrence risk

Reproductive Outcomes

The good news? The rate of spontaneous pregnancy in BOTs treated with conservative surgery varies between 32 and 65%. Most pregnancies occur spontaneously, though some patients may require fertility treatments.

For those with bilateral disease, ultra-conservative surgery has significant reproductive advantages over the standard procedure, in terms of cumulative pregnancy rate and time to conceive.

Laparoscopic vs. Open Surgery

The surgical approach — laparoscopic versus open surgery — presents another important consideration in borderline ovarian tumor treatment.

Benefits and Limitations of Laparoscopy

Laparoscopic management offers several advantages:

• Reduced postoperative complications
• Shorter recovery time
• Better cosmetic results
• Fewer adhesions (important for fertility)

However, considerations exist regarding surgical approach. While traditional open surgery has been the gold standard for borderline ovarian tumors, recent advances in laparoscopic techniques and surgeon training are narrowing the gap. With experienced surgeons and proper technique, laparoscopic outcomes are becoming increasingly comparable to open surgery. The key factors are complete surgical staging and minimizing cyst rupture — both achievable with advanced laparoscopic skills.

When Laparoscopy Works Best

Laparoscopy may be most appropriate for:

• Early-stage disease
• Tumors smaller than 10 cm
• When complete staging can be achieved
• Experienced laparoscopic surgeons

Recurrent Disease Management

Recurrence after initial treatment requires a different therapeutic approach. 25% of recurrences are diagnosed after 5 years, emphasizing the need for long-term follow-up.

Treatment Options for Recurrence

Second surgery: Most recurrences are treated with repeat surgery, especially when:

• Disease remains borderline (most common scenario)
• Complete resection appears feasible
• Patient desires continued fertility preservation

Chemotherapy considerations: Unlike invasive ovarian cancer, borderline tumors typically don’t require chemotherapy or radiation therapy, even when the disease is advanced or when small amounts of tumor remain after surgery. However, if the tumor comes back as invasive cancer (which is rare), chemotherapy may then be recommended.

Risk Factors for Recurrence

Several factors increase recurrence risk:

• Conservative surgery (especially cystectomy)
• Micropapillary pattern in serous tumors
• Microinvasion in borderline ovarian tumors
• Bilateral disease
• Advanced stage at diagnosis

Complete surgical eradication of ovarian tumors and peritoneal implants even if not visible macroscopically is the prerequisite in minimizing the risk of disease relapse.

Special Considerations in Treatment

Type of tumor: The type of borderline tumor you have influences your treatment plan. Serous borderline tumors are more likely to affect both ovaries and have a higher chance of spreading to the abdominal lining. However, they generally respond well to conservative treatment approaches.

Mucinous borderline tumors usually affect only one ovary and are less likely to spread throughout the abdomen. If you have a mucinous tumor, your surgeon may also remove your appendix to make sure the tumor didn’t actually start there. 

Because mucinous tumors have a higher risk of containing invasive cancer areas, doctors typically recommend removing the entire affected ovary and fallopian tube rather than just the tumor.

Microinvasion and micropapillary features: Some borderline tumors have special features that may affect how aggressively they need to be treated. 

Tumors with microinvasion (tiny areas where cancer cells invade surrounding tissue) have significantly higher recurrence rates: 17.4% compared to 7.8% for tumors without this feature. Serous tumors with a micropapillary pattern (a specific microscopic appearance) also tend to behave more aggressively and may require closer monitoring.

The Role of Adjuvant Therapy

One of the most important aspects of borderline ovarian tumor treatment is understanding what’s NOT needed. 

Chemotherapy and/or radiation therapy are not indicated for patients with more advanced-stage disease and microscopic or gross residual disease. Scant evidence exists that postoperative chemotherapy or radiation therapy alters the course of this disease in any beneficial way.

This represents a significant difference from invasive ovarian cancer management, where chemotherapy plays a central role.

Follow-Up: A Critical Component

Long-term surveillance forms an essential part of borderline ovarian tumor treatment. A close follow-up is recommended at least for the first two years after diagnosis, as previous studies have reported that most BOT recur during this period.

Recommended follow-up can include:

• Physical examination every 3 to 6 months initially
• Transvaginal ultrasound
• CA-125 monitoring (when initially elevated)
• Longer intervals as time progresses

The follow-up duration should extend well beyond typical cancer surveillance periods, as recurrences can occur decades after initial treatment. Also, each patient will have a specialized follow-up program based on their oncologist’s recommendations.

Making Treatment Decisions

Choosing the right treatment approach for borderline ovarian tumors requires collaboration between you and your healthcare team. Key factors to consider include:

• Your age and reproductive goals
• Tumor stage and histologic features
• Risk tolerance for recurrence
• Access to experienced surgical teams

The treatment landscape for borderline ovarian tumors continues evolving as we better understand these unique tumors. While the excellent prognosis provides reassurance, making informed treatment decisions remains crucial for optimizing both immediate and long-term outcomes.

Working with gynecologic oncologists experienced in borderline tumor management ensures you receive care tailored to these tumors’ specific characteristics and your individual circumstances. The goal remains clear: achieving cure while preserving quality of life and reproductive potential when desired.